1Colwell JA. Multifactorial aspects of treatment of the type 2 diabetic patient. Metabolism, 1997, 46Suppl 1: 1-4.
2American Diabetes Association. Implications of the Diabetes Control and Complications Trial. Diabetes Care, 2001, 24Suppl 1: S25-27.
3American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 2001, 24Suppl 1: S28-31.
4Kahn CR, Chen L, Cohen SE. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest, 2000, 106: 1305-1307.
5Unger RH, Zhou YT. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes, 2001, 50Suppl 1: S118-121.
6Cnop M, Hannaert JC, Hoorens A, et al. Inverse relationship between cytotoxicity of fatty acids in pancneatic islet cells and cellular triglyceride accumulation. Diabetes, 2001, 50: 1771-1771.
7McGarry JD. Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes, 2001, 50Suppl 2: 6-7.
8Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature, 2001, 489 : 307-312.
9American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care, 2000, 23Suppl 1: S61-62.
10American Diabetes Association. Smoking and diabetes. Diabetes Care, 2000, 23Suppl 1: S63-64.